Clinical Trials Logo

Pancreatic Neoplasms clinical trials

View clinical trials related to Pancreatic Neoplasms.

Filter by:

NCT ID: NCT05171517 Completed - Clinical trials for Pancreatic Carcinoma

Study on Microflora Characteristics of Pancreatic Solid Lesions Via Endoscopic Ultrasound-guided Fine Needle Aspiration/Biopsy

Start date: January 1, 2022
Phase:
Study type: Observational

Study objective: To describe the microflora characteristics of the pancreatic solid lesions via the tissue acquired via the endoscopic ultrasound-guided fine needle aspiration/biopsy (EUS-FNA/B). Study design: This is a prospective observational study.

NCT ID: NCT05170802 Recruiting - Pancreas Cancer Clinical Trials

Pancreatic Cancer & Surgical Resection

Start date: December 20, 2017
Phase:
Study type: Observational

Primary Objective(s) To collect clinical data related to the treatment outcomes of Pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with pancreatic cancer requiring surgical intervention. Secondary Objective(s) To collect data on adverse events and complications related to IRE treatment. The AHPBA (Americas Hepato-Pancreato-Biliary Association) will be responsible for data collection and will periodically audit the data for quality assurance purposes. The AHPBA will review outcomes reported by each participating Research Institution and if outcomes are in the lower percentile, the investigators will be offered support to analyze the reasons for the suboptimal outcomes and may seek support to improve outcomes. The participating Research Institutions will receive a certificate annually that acknowledges their participation in the Research Project.

NCT ID: NCT05169437 Active, not recruiting - Pancreatic Cancer Clinical Trials

Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

PAVO
Start date: March 15, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.

NCT ID: NCT05168527 Recruiting - Pancreatic Cancer Clinical Trials

The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients

Start date: September 3, 2021
Phase: Phase 2
Study type: Interventional

The aim of this study is to evaluate the safety and effectiveness of Fruquintinib combined with Albumin Paclitaxel and Gemcitabine on pancreatic cancer patients with liver metastases. Plan to enrollment 30 patients.

NCT ID: NCT05163977 Recruiting - Cancer of Pancreas Clinical Trials

Pancreatico Enteric Anastomosis Post Pancreaticoduodenectomy

PEAPP
Start date: June 12, 2021
Phase: N/A
Study type: Interventional

The aim of this study is to make a step for evaluation and presentation of a safe technique for pancreatico-jejunostomy that help in minimizing post-operative morbidity and mortality in pancreatic cancer patient by comparing Blumgart anastomosis with Cattell warren technique of anastomosis.

NCT ID: NCT05163028 Recruiting - Cancer Clinical Trials

A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

Start date: December 13, 2021
Phase: Phase 1
Study type: Interventional

A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS or EGFR mutations to determine the maximum tolerated dose and recommended Phase II dose of HBI-2376 and characterize its pharmacokinetic profile.

NCT ID: NCT05162118 Recruiting - Clinical trials for Advanced Pancreatic Cancer

Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer

Start date: March 8, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This is a multicenter, open, single-arm design clinical trial coducted in HSV-seropositive subjects with advanced pancreatic cancer to determine the safety, tolerability and preliminary efficacy of VG161 combined with PD-1 inhibitor (Nivolumab Injection).

NCT ID: NCT05159440 Recruiting - Gastric Cancer Clinical Trials

First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer

Start date: January 20, 2022
Phase: Phase 1
Study type: Interventional

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-MAB in patients with advanced cancer

NCT ID: NCT05156866 Recruiting - Gastric Cancer Clinical Trials

First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer

Start date: February 2, 2022
Phase: Phase 1
Study type: Interventional

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-ADC in patients with advanced cancer

NCT ID: NCT05155878 Recruiting - Surgery Clinical Trials

Prognostic Factors in Periampullary Tumors and Cysts

Start date: September 1, 2021
Phase:
Study type: Observational [Patient Registry]

The project aims at analysing prognostic and predictive factors involved in diagnostics and surgical treatment of cysts and tumors in the pancreas and periampullary region using both clinical data and blood and tissue samples for biomarker development and validation.